• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders.临床总体印象-严重程度评分作为精神分裂症和分裂情感性障碍缓解期常规评估的可靠指标。
Ann Gen Psychiatry. 2015 Feb 13;14:6. doi: 10.1186/s12991-015-0042-6. eCollection 2015.
2
Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy.使用简易版国际功能、残疾和健康分类应用程序评估精神分裂症和分裂情感性障碍患者的功能:意大利的一项验证研究。
Int J Ment Health Syst. 2015 Oct 31;9:37. doi: 10.1186/s13033-015-0030-x. eCollection 2015.
3
Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.是否真正缓解?一项受精神分裂症和分裂情感障碍影响的缓解患者的研究。
Psychiatry Res. 2013 Dec 30;210(3):739-44. doi: 10.1016/j.psychres.2013.08.022. Epub 2013 Sep 3.
4
Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances.用于评估临床缓解的一致性五因素阳性和阴性症状量表:对功能和认知表现的影响
Schizophr Res Cogn. 2014 Dec 8;1(4):187-192. doi: 10.1016/j.scog.2014.11.001. eCollection 2014 Dec.
5
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.精神分裂症或分裂情感障碍的临床稳定成年患者复发:等百分位链接和诊断测试准确性荟萃分析得出的循证标准。
Lancet Psychiatry. 2024 Jan;11(1):36-46. doi: 10.1016/S2215-0366(23)00364-4. Epub 2023 Nov 30.
6
Psychometric and clinical evaluation of schizophrenia remission criteria in outpatients with psychotic disorders.精神障碍门诊患者精神分裂症缓解标准的心理计量学和临床评估。
BMC Psychiatry. 2023 Mar 28;23(1):207. doi: 10.1186/s12888-023-04701-3.
7
Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study.精神分裂症和分裂情感性障碍患者缓解与康复中的性别差异:一项前瞻性队列研究的初步结果
Schizophr Res Treatment. 2012;2012:576369. doi: 10.1155/2012/576369. Epub 2012 Jan 16.
8
Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study.精神分裂症持续症状缓解:来自一项为期两年的前瞻性研究的过程和预测因素。
Schizophr Res. 2022 Jan;239:34-41. doi: 10.1016/j.schres.2021.11.023. Epub 2021 Nov 25.
9
Long-term outcome of schizoaffective disorder. Are there any differences with respect to schizophrenia?分裂情感性障碍的长期预后。与精神分裂症相比有哪些差异?
Riv Psichiatr. 2014 Jan-Feb;49(1):41-9. doi: 10.1708/1407.15624.
10
Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia.验证西班牙个人和社会表现量表(PSP)在稳定和不稳定精神分裂症门诊患者中的应用。
Rev Psiquiatr Salud Ment. 2011 Jan;4(1):9-18. doi: 10.1016/j.rpsm.2010.11.003. Epub 2011 Mar 10.

引用本文的文献

1
Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers.经皮耳迷走神经刺激治疗以阴性症状为主的难治性精神分裂症患者的疗效与安全性:一项随机临床试验及疗效敏感性生物标志物研究
Mol Psychiatry. 2025 Aug 26. doi: 10.1038/s41380-025-03132-8.
2
Non-adherence and predictors in patients with schizophrenia on second generation antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia.埃塞俄比亚阿马努埃尔精神专科医院中使用第二代抗精神病药物的精神分裂症患者的不依从性及预测因素
PLoS One. 2025 Mar 26;20(3):e0314403. doi: 10.1371/journal.pone.0314403. eCollection 2025.
3
Can Non-specific Blood Inflammatory Biomarkers Predict Recovery in Acute Transient Psychotic Disorder? A Prospective Observational Study.非特异性血液炎症生物标志物能否预测急性短暂性精神病性障碍的康复?一项前瞻性观察研究。
Indian J Psychol Med. 2025 Feb 14:02537176251317648. doi: 10.1177/02537176251317648.
4
Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort.抗胆碱能负担量表对精神分裂症医源性认知障碍的比较分析:来自多中心FACE-SZ队列的结果
Front Pharmacol. 2024 Jun 12;15:1403093. doi: 10.3389/fphar.2024.1403093. eCollection 2024.
5
Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials.鲁拉西酮治疗精神分裂症的疗效和安全性:八项短期、随机、双盲、安慰剂对照临床试验的系统评价和荟萃分析
Biomed Rep. 2024 Apr 11;20(6):91. doi: 10.3892/br.2024.1779. eCollection 2024 Jun.
6
Etomidate versus Propofol for Electroconvulsive Therapy in Patients with Major Depressive Disorders in Terms of Clinical Responses to Treatment: A Retrospective Analysis.依托咪酯与丙泊酚用于重度抑郁症患者电休克治疗的临床治疗反应对比:一项回顾性分析
Brain Sci. 2023 Jul 3;13(7):1023. doi: 10.3390/brainsci13071023.
7
Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders.越来越多的证据表明,脑源性神经营养因子是精神分裂症谱系障碍中抑郁症状的生物标志物。
Brain Sci. 2022 Dec 4;12(12):1666. doi: 10.3390/brainsci12121666.
8
Case report: Recovery of hallucinations and cognitive impairment after administration of donepezil in a patient with schizophrenia and carbon monoxide poisoning.病例报告:一名患有精神分裂症和一氧化碳中毒的患者在服用多奈哌齐后幻觉和认知障碍得到恢复。
Front Psychiatry. 2022 Nov 18;13:1071417. doi: 10.3389/fpsyt.2022.1071417. eCollection 2022.
9
Exploring the association between brain-derived neurotrophic factor levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients.探讨脑源性神经营养因子水平与撒丁岛精神病患者纵向心理病理和认知变化之间的关系。
Eur Psychiatry. 2022 Oct 25;65(1):e71. doi: 10.1192/j.eurpsy.2022.2333.
10
Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.阿立哌唑每月一次给药的长期真实世界有效性。意大利和西班牙临床实践中的治疗持续性及其相关因素:一项汇总分析。
Front Psychiatry. 2022 Apr 28;13:877867. doi: 10.3389/fpsyt.2022.877867. eCollection 2022.

本文引用的文献

1
Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.症状缓解标准再探讨:一项针对精神分裂症和分裂情感障碍患者的研究。
BMC Psychiatry. 2013 Sep 26;13:235. doi: 10.1186/1471-244X-13-235.
2
Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa.欧洲、中东和非洲地区精神科医生对精神分裂症患者功能的临床重要性、评估和管理的看法。
Ann Gen Psychiatry. 2013 Mar 26;12(1):8. doi: 10.1186/1744-859X-12-8.
3
A structured interview guide for global impressions: increasing reliability and scoring accuracy for CNS trials.用于全球印象的结构化访谈指南:提高 CNS 试验的可靠性和评分准确性。
Ann Gen Psychiatry. 2013 Jan 31;12(1):2. doi: 10.1186/1744-859X-12-2.
4
Remission in schizophrenia: critical and systematic review.精神分裂症的缓解:关键和系统评价。
Harv Rev Psychiatry. 2012 Nov-Dec;20(6):281-97. doi: 10.3109/10673229.2012.747804.
5
Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study.精神分裂症和分裂情感性障碍患者缓解与康复中的性别差异:一项前瞻性队列研究的初步结果
Schizophr Res Treatment. 2012;2012:576369. doi: 10.1155/2012/576369. Epub 2012 Jan 16.
6
Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? results of a retrospective study.未治疗精神病持续时间是否预测精神分裂症障碍的极长期结局?一项回顾性研究的结果。
Ann Gen Psychiatry. 2012 Aug 2;11(1):21. doi: 10.1186/1744-859X-11-21.
7
Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population.精神分裂症的缓解:在门诊人群中进行的横断面研究和 6 个月随访期及 1 年观察性治疗研究的结果。
Ann Gen Psychiatry. 2012 Jan 5;11(1):1. doi: 10.1186/1744-859X-11-1.
8
Persistent cognitive dysfunction despite clinical improvement in schizophrenia: a 10-year follow-up study.精神分裂症临床症状改善后仍存在持续性认知功能障碍:一项10年随访研究
J Psychiatr Pract. 2011 May;17(3):194-9. doi: 10.1097/01.pra.0000398412.67115.5c.
9
Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.缓解但仍受损?精神分裂症患者的有症状缓解与功能性缓解。
Eur Psychiatry. 2012 Aug;27(6):401-5. doi: 10.1016/j.eurpsy.2011.01.012. Epub 2011 May 12.
10
Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance.精神分裂症患者的症状缓解:与社会功能、生活质量和神经认知表现的关系。
Schizophr Res. 2011 Jul;129(2-3):133-6. doi: 10.1016/j.schres.2011.04.001. Epub 2011 Apr 22.

临床总体印象-严重程度评分作为精神分裂症和分裂情感性障碍缓解期常规评估的可靠指标。

Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders.

作者信息

Pinna Federica, Deriu Luca, Diana Enrica, Perra Valeria, Randaccio Rachele Pisu, Sanna Lucia, Tusconi Massimo, Carpiniello Bernardo

机构信息

Department of Public Health, Clinical and Molecular Medicine-Unit of Psychiatry, University of Cagliari, Via Liguria 13, 09127 Cagliari, Italy.

出版信息

Ann Gen Psychiatry. 2015 Feb 13;14:6. doi: 10.1186/s12991-015-0042-6. eCollection 2015.

DOI:10.1186/s12991-015-0042-6
PMID:25699085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4332923/
Abstract

AIMS

This study aimed to compare the performance of Positive and Negative Syndrome Scale (PANSS) symptom severity criteria established by the Remission in Schizophrenia Working Group (RSWG) with criteria based on Clinical Global Impression (CGI) severity score. The 6-month duration criterion was not taken into consideration.

METHODS

A convenience sample of 112 chronic psychotic outpatients was examined. Symptomatic remission was evaluated according to RSWG severity criterion and to a severity criterion indicated by the overall score obtained at CGI-Schizophrenia (CGI-SCH) rating scale (≤3) (CGI-S).

RESULTS

Clinical remission rates of 50% and 49.1%, respectively, were given by RSWG and CGI-S, with a significant level of agreement between the two criteria in identifying remitted and non-remitted cases. Mean scores at CGI-SCH and PANSS scales were significantly higher among remitters, independent of the remission criteria adopted. Measures of cognitive functioning were largely independent of clinical remission evaluated according to both RSWG and CGI-S. When applying RSWG and CGI-S criteria, the rates of overall good functioning yielded by Personal and Social Performance scale (PSP) were 32.1% and 32.7%, respectively, while the mean scores at PSP scale differed significantly between remitted and non-remitted patients, independent of criteria adopted. The proportion of patients judged to be in a state of well-being on Social Well-Being Under Neuroleptics-Short Version scale (SWN-K) were, respectively, 66.1% and 74.5% among remitters according to RSWG and CGI-S; the mean scores at the SWN scale were significantly higher only among remitters according to CGI-S criteria.

CONCLUSIONS

CGI severity criteria may represent a valid and user-friendly alternative for use in identifying patients in remission, particularly in routine clinical practice.

摘要

目的

本研究旨在比较精神分裂症缓解工作组(RSWG)制定的阳性和阴性症状量表(PANSS)症状严重程度标准与基于临床总体印象(CGI)严重程度评分的标准。未考虑6个月病程标准。

方法

对112例慢性精神病门诊患者进行便利抽样检查。根据RSWG严重程度标准和CGI精神分裂症量表(CGI-SCH)评分量表(≤3)(CGI-S)获得的总分所指示的严重程度标准评估症状缓解情况。

结果

RSWG和CGI-S的临床缓解率分别为50%和49.1%,在识别缓解和未缓解病例方面,这两个标准之间具有显著的一致性水平。无论采用何种缓解标准,缓解者在CGI-SCH和PANSS量表上的平均得分均显著更高。认知功能测量在很大程度上独立于根据RSWG和CGI-S评估的临床缓解情况。应用RSWG和CGI-S标准时,个人和社会功能量表(PSP)产生的总体良好功能率分别为32.1%和32.7%,而缓解和未缓解患者在PSP量表上的平均得分存在显著差异,与所采用的标准无关。根据RSWG和CGI-S,在缓解者中,使用抗精神病药物下的社会幸福感简版量表(SWN-K)判断处于幸福状态的患者比例分别为66.1%和74.5%;仅根据CGI-S标准,缓解者在SWN量表上的平均得分显著更高。

结论

CGI严重程度标准可能是用于识别缓解期患者的一种有效且用户友好的替代方法,尤其是在常规临床实践中。